Pemigatinib

Summarized by Plex Health
Last Updated: 02 May 2022

Pemigatinib is used in adults to deal with bile duct cancer that has infected other components of the body or can not be gotten rid of with surgical treatment. Pemigatinib is usually offered after your cancer has been treated with another medication. Pemigatinib may be used for functions not listed in this medication guide. Both males and females making use of pemigatinib should use efficient birth control to avoid pregnancy. An optometrist will require to examine your eyes prior to you begin taking this medication, and every 2 to 3 months while you are taking it. Pemigatinib can cause you to have high levels of phosphate in your blood. Your cancer therapies might be delayed based on the outcomes. As a problem of approval, a confirmatory trial has to show that pemigatinib provides a professional benefit in these patients. Definition from the NCI Drug Dictionary, Detailed scientific meaning and other names for this medicine. Drugs are typically examined to figure out if they can aid treat or stop conditions other than the ones they are approved for. This patient info sheet applies only to approved uses the medicine. Nonetheless, much of the details might also apply to unapproved uses that are being studied. Targeted Cancer Therapies. It is used in patients who have already tried cancer therapy before and have a certain type of abnormal FGFR2 genetics in their cancer. Your doctor will test for the presence of this gene. Pemigatinib is an antineoplastic agent. It conflicts with the growth of cancer cells, which are eventually ruined by the body. This medication is readily available only with your physician's prescription.

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

** If you believe that content on the Plex is summarised improperly, please, contact us, and we will get rid of it quickly; please, send an email with a brief explanation.

PubChem - CovalentUnitCount

(Table source)
CIDMolecularFormulaMolecularWeightCanonicalSMILESIsomericSMILESInChIInChIKeyIUPACNameXLogPExactMassMonoisotopicMassTPSAComplexityChargeHBondDonorCountHBondAcceptorCountRotatableBondCountHeavyAtomCountIsotopeAtomCountAtomStereoCountDefinedAtomStereoCountUndefinedAtomStereoCountBondStereoCountDefinedBondStereoCountUndefinedBondStereoCountCovalentUnitCount
86705695C24H27F2N5O4487.5CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5InChI=1S/C24H27F2N5O4/c1-4-30-21-14(11-27-23-16(21)9-15(28-23)13-29-5-7-35-8-6-29)12-31(24(30)32)22-19(25)17(33-2)10-18(34-3)20(22)26/h9-11H,4-8,12-13H2,1-3H3,(H,27,28)HCDMJFOHIXMBOV-UHFFFAOYSA-N11-(2,6-difluoro-3,5-dimethoxyphenyl)-13-ethyl-4-(morpholin-4-ylmethyl)-5,7,11,13-tetrazatricyclo[7.4.0.02,6]trideca-1,3,6,8-tetraen-12-one1.8487.20311068487.2031106883.273101863500000001
*** If you want us to remove all links leading to your domain from Plex.page and never use your website as a source of the "Online Knowledge", please contact us using a corporate email and we will remove everything in 10 business days.

logo

Plex Page is a Biology & Health Sciences "Online Knowledge Base," where a machine summarizes all the summaries.